Kodiak Sciences (KOD)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal d...
- Open
- 40.390
- High
- 40.900
- Low
- 37.990
- Prev. Close
- 39.840
- Volume
- 509.12K
- Turnover
- 19.77M
- Avg Price
- 38.827
- Bid/Ask Ratio
- --
- Amplitude
- 7.30%
- 52wk High
- 47.842
- Volume Ratio
- 1.12
- Turnover Ratio
- 1.30%
Kodiak Sciences Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$69.0080.02%
Forecast & RatingStrong buy
6analysts
- Strong buy83.33%
- Buy16.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 2 days ago, 03:00 PM
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1% - Time to Sell?
- Market Beat · Aug 19 at 07:12 AM
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences
- Tip Ranks · Aug 17 at 04:20 PM
3 Best Stocks With 75%+ Upside to Buy This Week, According to Analysts
- Simplywall · Aug 16 at 10:44 AM
Kodiak Sciences (KOD) Is Down 8.9% After Wider Q2 Losses And KSI-101 Trial Milestone – Has The Bull Case Changed?
- Market Beat · Aug 14 at 10:40 AM
Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?
- StockTitan · Aug 10 at 07:43 AM
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema | KOD Stock News
